^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Non Small Cell Lung Cancer
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Encorafenib is indicated:...in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

    Excerpt:
    ...- Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay or the presence of other BRAFV600 mutations other than V600E (i.e. K or D) will be considered...
    Trial ID:
    PHAROS
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer. Estudio para evaluar la combinación de Encorafenib + Binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E

    Excerpt:
    ...Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay. ...
    Trial ID:
    2019-000417-37
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Invest New Drugs
    Title:

    Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

    Published date:
    08/26/2021
    Excerpt:
    We report the case of 70-year-old man affected by BRAF V600-mutant NSCLC with bilateral lung and bone metastases. First-line treatment with encorafenib (450 mg once daily) and binimetinib (45 mg twice daily) was administered within a clinical trial. At the first radiological assessment, computed tomography (CT) scan showed a partial response...
    DOI:
    10.1007/s10637-021-01166-7